Ospemifene for Genitourinary Syndrome of Menopause: Patient Selection

References

• Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61:508–516. doi:10.1097/GRF.0000000000000380
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Climacteric. 2014;17(5):557–563. doi:10.3109/13697137.2014.946279
   PubMed Web of Science ®Google Scholar
• ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93–6. doi:10.1097/AOG.0000000000001351
   PubMed Web of Science ®Google Scholar
• Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2021;191:269–275. doi:10.1007/s10549-021-06436-9
   PubMed Web of Science ®Google Scholar
• Kingsberg SA. Vaginal health and lubricants. Post Reprod Health. 2016;22(4):171–172.
   Google Scholar
• Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22(8):845–849. doi:10.1097/GME.0000000000000401
   PubMed Web of Science ®Google Scholar
• Murina F, Di Francesco S, Oneda S. Vulvar vestibular effects of ospemifene: a pilot study. Gynecol Endocrinol. 2018;34(7):631–635. doi:10.1080/09513590.2018.1427717
   PubMed Web of Science ®Google Scholar
• Goldstein SW, Winter AG, Goldstein I. Improvements to the vulva, vestibule, urethral meatus, and vagina in women treated with ospemifene for moderate to severe dyspareunia: a prospective vulvoscopic pilot study. Sex Med. 2018;6(2):154–161. doi:10.1016/j.esxm.2018.03.002
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA, et al. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623–630. doi:10.1097/gme.0b013e318279ba64
   PubMed Web of Science ®Google Scholar
• Lino Del Pup & Rafael Sánchez-Borrego. Ospemifene efficacy and safety data in women with vulvovaginal atrophy. Gynecological Endocrinol. 2020. doi:10.1080/09513590.2020.1757058
   Web of Science ®Google Scholar
• Drugs@FDA. FDA approved drug products: OSPHENAVR (ospemifene) 60mg tablet; 2019. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=over-view.process&varApplNo=203505. Accessed May 23, 2024.
   Google Scholar
• Bondi C, Ferrero S, Scala C, et al. Pharmacokinetics, pharmaco- dynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause. Expert Opin Drug Metab Toxicol. 2016;12(10):1233–1246. doi:10.1080/17425255.2016.1218847
   PubMed Web of Science ®Google Scholar
• Lobo RA. Efficacy of ospemifene in the treatment of moderate to severe vaginal dryness, a symptom of vulvovaginal atrophy, due to menopause. Fertil Steril. 2014;101(6):1536–1543.
   Google Scholar
• Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17:480–486. doi:10.1097/gme.0b013e3181c1ac01
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12- month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182. doi:10.3109/13697137.2013.834493
   PubMed Web of Science ®Google Scholar
• Bruyniks N, De Gregorio F, Gibbs T, et al. Safety of ospemifene during real-life use. J Gynecol Women’s Health. 2018;9(3):555762. doi:10.19080/JGWH.2018.09.555762
   Google Scholar
• Kagan R. Long-term safety and efficacy of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. J Sex Med. 2013;10(8):2031–2038.
   Google Scholar
• Simon JA, Ferenczy A, Black D, et al. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis. Menopause. 2023;30(8):855–866. doi:10.1097/GME.0000000000002211
   PubMed Web of Science ®Google Scholar
• Senshio®. Summary of product Characteristics; 2024.
   Google Scholar
• Russo E, Misasi G, Montt-Guevara MM, Giannini A, Simoncini T. Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy. Climacteric. 2023;26(3):284–288. doi:10.1080/13697137.2023.2184251
   PubMed Web of Science ®Google Scholar
• Novara L, Giuseppe L, Mancarella M, Capeve R, Canale E, Biglia N. Potential effectiveness of ospemifene on detrusor overactivity in patients with vaginal atrophy. Maturitas. 2020;138:58–61. doi:10.1016/j.maturitas.2020.05.001
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. Gynecol Endocrinol. 2017;33(12):942–945. doi:10.1080/09513590.2017.1323859
   PubMed Web of Science ®Google Scholar
• Schiavi MC, D’Oria O, Aleksa N, et al. Usefulness of Ospemifene in the treatment of urgency in menopausal patients affected by mixed urinary incontinence underwent mid-urethral slings surgery. Gynecol Endocrinol. 2019;35(2):155–159. doi:10.1080/09513590.2018.1500534
   PubMed Web of Science ®Google Scholar
• Constantine GD, Kagan R, Miller PD. Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women. Menopause. 2016;23(6):638–644. doi:10.1097/GME.0000000000000619
   PubMed Web of Science ®Google Scholar
• Archer DF, Altomare C, Jiang W, et al. Ospemifene’s effects on lipids and coagulation factors: a post hoc analysis of Phase 2 and 3 clinical trial data. Menopause. 2017;24(10):1167–1174. doi:10.1097/GME.0000000000000900
   PubMed Web of Science ®Google Scholar
• Nappi RE, Murina F, Perrone G, et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol. 2017;69(4):370–380. doi:10.23736/S0026-4784.17.04064-3
   PubMedGoogle Scholar
• Management | Menopause | CKS | NICE. National Institution of Clinical Excellence (Website: scenario: management of menopause, perimenopause, or premature ovarian insufficiency; 2024.
   Google Scholar